{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    8,
    9,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Enzalutamide",
        "type": {
          "id": "22f38079-9ba2-43f8-9ff7-6c3cc3c54192",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "514f3221-ec83-46ec-bcdc-55b0b8522fce",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "A second generation androgen receptor (AR) inhibitor",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "74308902-104c-4718-95cb-5d1c180a1be3",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "b0bfe75e-c7cb-4dd3-8539-47a2386734e6",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules identical in appearance to enzalutamide",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Androgen Deprivation Therapy (ADT)",
        "type": {
          "id": "01d716e1-92bb-4e3a-a304-eb6a232b2b3b",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "4ca93ec0-014c-4899-b990-fa30e312bac0",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "LHRH agonist or antagonist or history of bilateral orchiectomy",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Docetaxel",
        "type": {
          "id": "4978f58d-f873-462f-9977-30ce83501c72",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "d5cbc497-a2c2-4e92-9149-c037d4b480c4",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Up to 6 cycles permitted if completed within 2 months of Day 1"
      },
      {
        "id": "int_5",
        "name": "5-alpha reductase inhibitors",
        "type": {
          "id": "0b7a65e8-8822-4d50-a72d-500afaf811e4",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "16584c76-f0d7-4739-940a-cdc7cf2d58c3",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited (e.g., finasteride, dutasteride)"
      },
      {
        "id": "int_6",
        "name": "Estrogens",
        "type": {
          "id": "2a19eaba-0e7f-499c-820b-e86d1488d83a",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "925db39b-81bd-405f-8c4c-179ce7d75c04",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited"
      },
      {
        "id": "int_7",
        "name": "Cyproterone acetate",
        "type": {
          "id": "f7038c41-cb1f-4914-b243-9c5a606f757b",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "b5755dde-264d-411b-a456-b5f298ea9f18",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited"
      },
      {
        "id": "int_8",
        "name": "Systemic glucocorticoids",
        "type": {
          "id": "bb74e0c6-6aa4-4d02-afa1-487f75cb1e30",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "0d436dbe-602a-4baf-b407-6bbb633e18fa",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited if > 10 mg/day prednisone equivalent for prostate cancer treatment"
      },
      {
        "id": "int_9",
        "name": "Herbal medications",
        "type": {
          "id": "6cbf260e-483e-434f-9fa0-d2af129e55b6",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "2c2e851b-3b18-4670-9173-8b62270f5edd",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited if known hormonal antiprostate cancer activity (e.g., saw palmetto)"
      },
      {
        "id": "int_10",
        "name": "Androgens",
        "type": {
          "id": "408d4699-1044-4e8b-a625-ace5f669171f",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "fb0ef21d-6925-472a-9b22-2bbbc595d356",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited (e.g., testosterone, dihydroepiandrosterone)"
      },
      {
        "id": "int_11",
        "name": "Bisphosphonates or denosumab",
        "type": {
          "id": "45a93316-5bc0-4102-a695-fbb315b3ec2d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "1b2f6bc7-6e2d-4d9d-8e5f-370a9c9b1752",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited unless stabilized for 2 weeks prior to randomization or for osteoporosis"
      },
      {
        "id": "int_12",
        "name": "Strong CYP2C8 inhibitors",
        "type": {
          "id": "ca815a1c-725a-4d04-8f05-8fea1e6fbe91",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "d0c1a290-9c54-4139-b179-4c9dea645f3f",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Avoided; if necessary, reduce enzalutamide dose to 80 mg (e.g., gemfibrozil)"
      },
      {
        "id": "int_13",
        "name": "Strong/Moderate CYP3A4 inducers",
        "type": {
          "id": "12fd6658-cb08-434c-abad-8812c9c1ad64",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "6b38b27c-a2d3-456f-818c-e8f68b57e85a",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Avoided (e.g., carbamazepine, rifampin, St. John’s Wort)"
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Enzalutamide capsules",
        "administrableDoseForm": {
          "id": "1a318a7e-ddec-43df-8f85-07c36a02e7b2",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "239f8e12-9aa4-458f-8fae-32f4f2f50cdc",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "7ff5455e-c2f7-4839-b497-297245ded636",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "40 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Astellas Pharma Global Development, Inc"
      },
      {
        "id": "prod_2",
        "name": "Placebo capsules",
        "administrableDoseForm": {
          "id": "5e52da14-f232-49b0-95b1-4599454d96b0",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "036a04d1-261f-4360-8b3e-c4a83faf006f",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "4d81cf67-a0af-435f-984d-7d41c4130749",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "0 mg",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Astellas Pharma Global Development, Inc"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Standard Enzalutamide Regimen",
        "instanceType": "Administration",
        "dose": "160 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Until radiographic disease progression or unacceptable toxicity"
      },
      {
        "id": "admin_2",
        "name": "Reduced Enzalutamide Regimen (Toxicity)",
        "instanceType": "Administration",
        "dose": "120 mg or 80 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "As needed for toxicity management"
      },
      {
        "id": "admin_3",
        "name": "Reduced Enzalutamide Regimen (CYP2C8 Interaction)",
        "instanceType": "Administration",
        "dose": "80 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "During coadministration with strong CYP2C8 inhibitor"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Enzalutamide",
        "instanceType": "Substance",
        "description": "Active pharmaceutical ingredient; formerly MDV3100"
      },
      {
        "id": "sub_2",
        "name": "N-desmethyl enzalutamide",
        "instanceType": "Substance",
        "description": "Major active human metabolite"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 13,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Enzalutamide",
        "role": "Investigational Product",
        "description": "A second generation androgen receptor (AR) inhibitor"
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo capsules identical in appearance to enzalutamide"
      },
      {
        "name": "Androgen Deprivation Therapy (ADT)",
        "role": "Background Therapy",
        "description": "LHRH agonist or antagonist or history of bilateral orchiectomy"
      },
      {
        "name": "Docetaxel",
        "role": "Prior Medication",
        "description": "Up to 6 cycles permitted if completed within 2 months of Day 1"
      },
      {
        "name": "5-alpha reductase inhibitors",
        "role": "Concomitant Medication",
        "description": "Prohibited (e.g., finasteride, dutasteride)"
      },
      {
        "name": "Estrogens",
        "role": "Concomitant Medication",
        "description": "Prohibited"
      },
      {
        "name": "Cyproterone acetate",
        "role": "Concomitant Medication",
        "description": "Prohibited"
      },
      {
        "name": "Systemic glucocorticoids",
        "role": "Concomitant Medication",
        "description": "Prohibited if > 10 mg/day prednisone equivalent for prostate cancer treatment"
      },
      {
        "name": "Herbal medications",
        "role": "Concomitant Medication",
        "description": "Prohibited if known hormonal antiprostate cancer activity (e.g., saw palmetto)"
      },
      {
        "name": "Androgens",
        "role": "Concomitant Medication",
        "description": "Prohibited (e.g., testosterone, dihydroepiandrosterone)"
      },
      {
        "name": "Bisphosphonates or denosumab",
        "role": "Concomitant Medication",
        "description": "Prohibited unless stabilized for 2 weeks prior to randomization or for osteoporosis"
      },
      {
        "name": "Strong CYP2C8 inhibitors",
        "role": "Concomitant Medication",
        "description": "Avoided; if necessary, reduce enzalutamide dose to 80 mg (e.g., gemfibrozil)"
      },
      {
        "name": "Strong/Moderate CYP3A4 inducers",
        "role": "Concomitant Medication",
        "description": "Avoided (e.g., carbamazepine, rifampin, St. John’s Wort)"
      }
    ],
    "products": [
      {
        "name": "Enzalutamide capsules",
        "doseForm": "Capsule",
        "strength": "40 mg",
        "manufacturer": "Astellas Pharma Global Development, Inc"
      },
      {
        "name": "Placebo capsules",
        "doseForm": "Capsule",
        "strength": "0 mg",
        "manufacturer": "Astellas Pharma Global Development, Inc"
      }
    ],
    "substances": [
      {
        "name": "Enzalutamide",
        "description": "Active pharmaceutical ingredient; formerly MDV3100"
      },
      {
        "name": "N-desmethyl enzalutamide",
        "description": "Major active human metabolite"
      }
    ],
    "administrations": [
      {
        "name": "Standard Enzalutamide Regimen",
        "dose": "160 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Until radiographic disease progression or unacceptable toxicity"
      },
      {
        "name": "Reduced Enzalutamide Regimen (Toxicity)",
        "dose": "120 mg or 80 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "As needed for toxicity management"
      },
      {
        "name": "Reduced Enzalutamide Regimen (CYP2C8 Interaction)",
        "dose": "80 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "During coadministration with strong CYP2C8 inhibitor"
      }
    ],
    "devices": []
  }
}